

REMARKS

The Examiner rejected claims 3, 4, and 11-21, while objecting to claim 4. Claims 3 and 14-21 have been cancelled herein without prejudice, and new claim 22 has been added. Thus, claims 4, 11-13, and 22 are pending.

Claim 4 has been amended herein to be in independent form as indicated above. In addition, claims 11-13 have been amended herein to depend from claim 4. New claim 22 recites that the self C5 amino acid segment comprises a self C5a amino acid segment. Applicants' specification fully supports these amendments. For example, page 3, lines 29-31 disclose that a composition can contain an adjuvant and a polypeptide. Thus, no new matter has been added.

In light of these amendments and the following remarks, Applicants respectfully request reconsideration and allowance of claims 4, 11-13, and 22.

Rejections under 35 U.S.C. § 102

The Examiner rejected claims 14 and 16-18 under 35 U.S.C. § 102(a) and (e) as allegedly being anticipated by U.S. Patent No. 7,063,847 (the '847 patent). Claims 14 and 16-18 have been cancelled herein without prejudice. Thus, these rejections are moot.

Rejections under 35 U.S.C. § 103(a)

The Examiner rejected claims 3 and 11-13 under 35 U.S.C. § 103(a) as allegedly being unpatentable over the '847 patent in view of the Oshima *et al.* reference (*Immunol. Lett.*, 60:7-12 (1998)). The Examiner also rejected claims 15 and 19-21 under 35 U.S.C. § 103(a) as allegedly being unpatentable over the '847 patent in view of the Na *et al.* reference (*Clin. Diag. Lab. Immunol.*, 6(3):429-433 (1999)).

Claims 3, 15, and 19-21 have been cancelled herein without prejudice. In addition, claims 11-13 have been amended to depend from claim 4. Thus, these rejections are moot.

Claim Objections

The Examiner objected to claim 4 as being dependent upon a rejected base claim, but stated that claim 4 would be allowable if rewritten in independent form including all of the

limitations of the base claim and any intervening claims. Applicants respectfully submit that claim 4, which has been amended herein as indicated above, is in condition for allowance even though the amendment did not include all the limitations of cancelled claim 3.


CONCLUSION

Applicants submit that claims 4, 11-13, and 22 are in condition for allowance, which action is respectfully requested. The Examiner is invited to telephone the undersigned agent if such would further prosecution.

Please apply any other charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: September 17, 2007



J. Patrick Finn III, Ph.D.
Reg. No. 44,109

Fish & Richardson P.C.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696